# Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care

> **NCT03743649** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 110 (actual)

## Conditions studied

- Delirium
- Locally Advanced Malignant Neoplasm
- Metastatic Malignant Neoplasm
- Recurrent Malignant Neoplasm

## Interventions

- **DRUG:** Haloperidol
- **DRUG:** Lorazepam
- **OTHER:** Placebo
- **OTHER:** Quality-of-Life Assessment
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT03743649
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-07-17
- **Primary completion:** 2026-02-28
- **Final completion:** 2026-12-31
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2025-12-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03743649

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03743649, "Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03743649. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*